Skip to main content

Table 2 Correlation coefficients for the association of serum periostin and TNC levels with subject characteristics in asthmatic patients

From: Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

  Periostin TNC
rs P value rs P value
Sex (male) − 0.033 0.711 − 0.025 0.780
Age (years) 0.261 0.003* − 0.074 0.410
Age at asthma onset (years) 0.283 0.001* − 0.019 0.831
Duration of asthma (years) − 0.165 0.066 0.019 0.833
BMI (kg/m2) − 0.071 0.428 0.029 0.749
Pack-year smoking history (pack year) 0.014 0.878 − 0.032 0.722
GINA step 4 + 5 − 0.224 0.012* 0.274 0.002*
AERD 0.119 0.186 0.132 0.142
Atopic dermatitis − 0.016 0.857 0.003 0.969
Allergic rhinitis − 0.041 0.651 − 0.027 0.763
Chronic sinusitis 0.088 0.329 0.026 0.771
Daily dose of ICS (FP equivalent dose, µg) − 0.194 0.029* 0.206 0.020*
Daily dose of OCS (PSL equivalent dose, mg) − 0.068 0.446 0.096 0.286
ACT score, n = 125 0.240 0.007* − 0.108 0.232
FeNO (ppb) 0.319 < 0.001* 0.057 0.529
Peripheral neutrophils (cells/μL) − 0.124 0.168 0.189 0.034*
Peripheral eosinophils (cells/μL) 0.360 < 0.001* 0.063 0.486
Serum IgE (IU/mL) 0.110 0.221 0.259 0.003*
Th2-high 0.195 0.029* 0.046 0.609
FVC (L) − 0.167 0.061 − 0.056 0.536
%FVC (predicted, %) − 0.047 0.604 − 0.104 0.246
FEV1 (L) − 0.167 0.061 − 0.099 0.271
%FEV1 (predicted, %) − 0.203 0.023* − 0.042 0.642
FEV1/FVC ratio (%) − 0.084 0.349 − 0.149 0.096
PEF (L/s) − 0.146 0.103 − 0.057 0.524
%PEF (predicted, %) − 0.024 0.786 − 0.103 0.252
MMF (L) − 0.250 0.005* − 0.058 0.522
%MMF (predicted, %) − 0.195 0.028* − 0.140 0.118
  1. ACT asthma control test, AERD aspirin-exacerbated respiratory disease, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, IgE immunoglobulin E, MMF mid-maximal flow rate, OCS oral corticosteroids, PEF peak expiratory flow, PSL prednisolone, Th2 T-helper cell type 2, TNC tenascin-C
  2. *P < 0.05
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us

\